Cancer Research Institute awards $30.2 million in grants and fellowships to support basic and clinical research in immunology and cancer immunotherapy.
The Phase 2 clinical trial will analyze blood-based biomarkers versus conventional radiography for cancer patients treated with immunotherapy; findings could change direction of lung cancer treatment
The Cancer Research Institute (CRI) was informed on July 16, 2020, that one of our vendors, Blackbaud, experienced a data incident in May of this year.
30 days of immunotherapy education and awareness programming for patients, caregivers, and the others celebrating advances in immuno-oncology research and treatment
Report reveals that the cellular immunotherapy landscape continues to expand, with 472 more cellular therapies in development now than one year ago.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
Rare and ultra-rare cancers affect around 20,000 people in the United States alone, according to Foundation Medicine, Inc. Immunotherapy research in some of the more common cancers and the identification of biomarkers that can predict patient responses is opening this new approach to cancer treatment up to patients whose cancers currently receive little direct attention.
Cancer is not “one-size-fits-all” and neither are its treatments, especially when it comes to immunotherapy. Learn how CRI is helping more people overcome cancer.